Your browser is no longer supported. Please, upgrade your browser.
Settings
CELG Celgene Corporation daily Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E15.13 EPS (ttm)5.20 Insider Own0.20% Shs Outstand733.22M Perf Week0.33%
Market Cap57.65B Forward P/E7.70 EPS next Y10.21 Insider Trans-2.42% Shs Float722.37M Perf Month-14.61%
Income4.12B PEG0.76 EPS next Q2.09 Inst Own78.30% Short Float1.70% Perf Quarter-18.51%
Sales13.58B P/S4.25 EPS this Y109.10% Inst Trans-5.79% Short Ratio1.64 Perf Half Y-25.23%
Book/sh6.91 P/B11.38 EPS next Y19.89% ROA- Target Price113.38 Perf Year-32.65%
Cash/sh6.46 P/C12.16 EPS next 5Y19.81% ROE- 52W Range74.13 - 147.17 Perf YTD-24.66%
Dividend- P/FCF- EPS past 5Y25.80% ROI20.00% 52W High-46.57% Beta1.43
Dividend %- Quick Ratio2.40 Sales past 5Y18.70% Gross Margin96.40% 52W Low6.07% ATR2.33
Employees7467 Current Ratio2.50 Sales Q/Q19.40% Oper. Margin- RSI (14)39.40 Volatility2.64% 2.88%
OptionableYes Debt/Eq3.92 EPS Q/Q-4.20% Profit Margin- Rel Volume0.80 Prev Close79.54
ShortableYes LT Debt/Eq3.92 EarningsMay 04 BMO Payout- Avg Volume7.51M Price78.63
Recom2.30 SMA20-5.17% SMA50-9.01% SMA200-26.50% Volume6,023,183 Change-1.14%
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Dec-08-17Upgrade Atlantic Equities Neutral → Overweight
Oct-27-17Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-27-17Reiterated SunTrust Buy $156 → $127
Oct-27-17Reiterated Barclays Equal Weight $135 → $105
Oct-27-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-26-17Downgrade Wells Fargo Outperform → Market Perform
Oct-24-17Initiated Guggenheim Buy $160
May-26-18 11:07AM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-25-18 10:50PM  CELGENE 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against Celgene Corporation - CELG Business Wire
03:46PM  CELGENE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Celgene Corporation To Contact The Firm PR Newswire
03:13PM  DEADLINE TUESDAY: INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 - CELG ACCESSWIRE
02:07PM  Celgene Hammered, Again, On 'Subpar' Success In Developing Drugs Investor's Business Daily
10:45AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $500K of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018 ACCESSWIRE
May-24-18 11:58PM  [$$] Celgenes Buybacks Are Coming Up Empty The Wall Street Journal
07:36PM  $100,000 Threshold: Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Celgene Corporation Investors (CELG) GlobeNewswire
04:18PM  Agios (AGIO) Progressing Well on Pipeline Amid Competition Zacks
11:23AM  [$$] Celgene's Buybacks Are Coming Up Empty The Wall Street Journal
11:14AM  Celgene Corporation -- Moody's: Celgene's accelerated share repurchase credit negative Moody's
11:07AM  Will Right to Try Bill Boost Biotech ETFs? ETF Trends
09:43AM  Oil Drags On Opening Trade; Dow Lags, Celgene Surges Investor's Business Daily
09:18AM  Celgene Shares Rise on Plans to Increase Stock Buybacks TheStreet.com
08:51AM  I Just Bought My First New Stock in 8 Months, and This Is It Motley Fool
07:34AM  Celgene shares jump 1.2% premarket on news of additional $3 billion share buyback MarketWatch
07:30AM  Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program Business Wire
06:31AM  Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio Motley Fool
May-23-18 04:24PM  Analysts Split: Celgene Tilts 'To Greater Risk' On Revlimid Challenges Investor's Business Daily
03:00PM  CELG EQUITY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018 GlobeNewswire
09:56AM  David's 5 Winning Stocks for a Thinking World: 2 Years Later, Has a Bet on Brains Paid Off? Motley Fool
09:34AM  Celgene Wins One Bull, Loses Another On Revlimid Potential Benzinga
09:26AM  Celgene Cratering to Four-Year Low Leaves Analysts Split Bloomberg
09:15AM  Warren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove It Motley Fool
May-22-18 07:18PM  The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Celgene Corporation (CELG) Business Wire
05:42PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Celgene Corporation To Contact The Firm GlobeNewswire
04:20PM  Why Amgen's In Trouble And Should Take Notes From Biogen, Celgene Investor's Business Daily
01:52PM  Celgene Corporation: How to Effectively Buy Into CELG Stock InvestorPlace
11:59AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 CELG GlobeNewswire
11:42AM  Celgene Forges Oncology Partnership With Germany's Evotec Benzinga
10:25AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018 ACCESSWIRE
08:56AM  Reviewing 5 Winning Stocks for a Thinking World, and Relishing 1 Thoughtful CEO Motley Fool
08:10AM  Today's Research Reports on Trending Tickers: Celgene and Foundation Medicine ACCESSWIRE
08:00AM  FINAL DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation (Nasdaq:CELG) To Contact The Firm GlobeNewswire
07:30AM  Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018 Business Wire
06:33AM  Celgene Strikes Strategic Partnership With Evotec Investopedia
06:31AM  3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists Motley Fool
May-21-18 09:30PM  Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Celgene Corporation (CELG) Business Wire
04:53PM  Celgene Plunges On Report Its Head Of Mergers Quietly Exited In April Investor's Business Daily
03:39PM  5 Top Stock Trades for Tuesday Morning InvestorPlace
May-20-18 08:27PM  Did Celgene Corporations (NASDAQ:CELG) Recent Earnings Growth Beat The Trend? Simply Wall St.
May-19-18 11:49AM  These Stocks Have Quadrupled in Just 1 Year Motley Fool
09:12AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
May-18-18 10:50PM  CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG GlobeNewswire
02:44PM  FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs InvestorPlace
01:44PM  NYSE trader: Expect explosive earnings growth over the next 4-5 quarters Yahoo Finance Video
May-17-18 06:07PM  Jounce Therapeutics Gets Throttled, Loses 35% Today Motley Fool
05:24PM  FDA names drugmakers accused of blocking cheaper generics Associated Press
04:48PM  The FDA Is Trying To 'Shame' Celgene, Gilead Here's Why It Won't Work Investor's Business Daily
04:01PM  FDA names drugmakers potentially acting to delay cheap generics Reuters
02:43PM  Nohla Therapeutics closes $45 million funding round to continue clinical trials American City Business Journals
01:09PM  The Punching Bag of Biotech Absorbs More Blows Bloomberg
11:29AM  [$$] Investors, Brace Yourselves for More Drug-Price Drama The Wall Street Journal
09:20AM  U.S. Names Drugmakers Gaming Safety System to Shield Profits Bloomberg
May-16-18 05:30PM  Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions Business Wire
03:30PM  INVESTOR ALERT: The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG) ACCESSWIRE
02:37PM  MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus Yahoo Finance Video
10:07AM  Hagens Berman Reminds Investors in Celgene Corporation (CELG) of the May 29, 2018 Securities Class Action Lead Plaintiff Deadline PR Newswire
08:20AM  Today's Research Reports on Trending Tickers: Celgene and Valeant Pharmaceuticals ACCESSWIRE
08:08AM  Your guide to the Trump drug price plan: who it affects and how MarketWatch
07:00AM  CRISPR Stocks Deserve a Second Look. Here's Why. Investopedia
May-15-18 04:19PM  [$$] Nohla Therapeutics Collects $45 Million Series B to Treat Blood Diseases The Wall Street Journal
01:55PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 - CELG ACCESSWIRE
01:00PM  Nohla Therapeutics Announces Closing of $45 Million Series B Financing GlobeNewswire
10:15AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018 ACCESSWIRE
09:55AM  Analyst: Trump's 'Naming And Shaming' Campaign To Build Pharma Headline Risk Benzinga
09:08AM  Your guide to the Trump drug price plan: who it affects and how MarketWatch
May-14-18 02:00PM  CELG SHAREHOLDER: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018 ACCESSWIRE
07:30AM  Celgene Corporation to Webcast at Upcoming Investor Conferences and Events Business Wire
May-12-18 07:16AM  Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc. Motley Fool
May-11-18 10:50PM  CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG GlobeNewswire
04:00PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 - CELG ACCESSWIRE
11:48AM  Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead TheStreet.com
11:40AM  Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon TheStreet.com
09:16AM  3 Growth Stocks at Deep-Value Prices Motley Fool
08:09AM  3 Growth Stocks for In-the-Know Investors Motley Fool
May-10-18 09:00PM  Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Celgene Corporation Investors (CELG) Business Wire
06:31PM  Cramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects CNBC
06:32AM  Even in This Rich Market, Celgene Is Offering Investors Value Motley Fool
May-09-18 04:55PM  bluebird bio Looks for Data Ahead Motley Fool
03:17PM  CLASS UPDATE: The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG) Business Wire
10:40AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018 ACCESSWIRE
08:12AM  3 Stocks That Turned $10,000 Into $1 Million Motley Fool
06:57AM  The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, U.S. Bancorp, Tesla and Celgene Zacks
04:06AM  Edited Transcript of CELG earnings conference call or presentation 4-May-18 1:00pm GMT Thomson Reuters StreetEvents
May-08-18 10:36AM  Top Analyst Reports for Berkshire Hathaway, Pfizer & U.S. Bancorp Zacks
May-07-18 03:22PM  CELG EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018 Business Wire
11:39AM  Celgene: If You Have to Be Downgraded Barrons.com
10:58AM  MARKETS: Soaring crude oil prices are lifting stocksbut it's only temporary Yahoo Finance Video
09:31AM  Are These 2 Biotech Laggards Ready to Rebound? Motley Fool
08:31AM  5 Key Things You Need to Know From Celgene's Q1 Earnings Update Motley Fool
08:12AM  Celgene shares get a lift on first-quarter beats, but long-term worries persist MarketWatch
May-05-18 10:16AM  Editas Medicine Starts a "Transformative" Year on a High Note Motley Fool
08:31AM  This Biotech Stock Could Be Like Buying Celgene in 2006 Motley Fool
May-04-18 04:55PM  Is Celgene's Beat-And-Raise Enough To Outweigh MS Drug Woes? Investor's Business Daily
02:35PM  Celgene CEO: Strong Q1 Led To Improved Full-Year Guidance Benzinga
12:54PM  Celgene Corporation (CELG) Q1 2018 Earnings Conference Call Transcript Motley Fool
12:31PM  Celgene Hasn't Earned the Benefit of the Doubt Bloomberg
12:29PM  Celgene Corporation Stock Pops on Q1 Earnings Beat InvestorPlace
10:35AM  Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength Zacks
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. to advance a PD-1 Inhibitor program for solid tumor cancers. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; and Prothena Corporation plc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alles Mark JCEO, CHAIRMAN OF BOARDMay 09Buy82.601,20899,784187,316May 17 04:08 PM
Curran TerrieMay 04Option Exercise0.002,50007,507May 08 04:56 PM
VESSEY RUPERTMay 04Option Exercise0.0078103,731May 08 04:36 PM
KELLOGG PETER NMay 04Option Exercise0.003,500050,831May 08 04:34 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 04Option Exercise0.003,5000187,627May 08 04:30 PM
LOUGHLIN JAMES JDirectorMar 12Option Exercise27.189,250251,41533,611Mar 13 04:22 PM
LOUGHLIN JAMES JDirectorMar 12Sale92.019,250851,09324,361Mar 13 04:22 PM
MARIO ERNESTDirectorFeb 23Sale94.4913,3701,263,29855,404Feb 26 04:11 PM
KAPLAN GILLADirectorFeb 20Sale94.839,250877,17876,301Feb 20 05:02 PM
Smith Scott AndrewSee RemarksFeb 17Option Exercise0.007,283051,748Feb 20 05:03 PM
KELLOGG PETER NSee RemarksFeb 17Option Exercise0.007,283049,660Feb 20 05:03 PM
Alles Mark JSee RemarksFeb 17Option Exercise0.007,2830186,187Feb 20 05:00 PM
KAPLAN GILLADirectorFeb 15Option Exercise27.189,250251,41594,801Feb 20 05:02 PM
KAPLAN GILLADirectorFeb 15Sale95.999,250887,89885,551Feb 20 05:02 PM
Alles Mark JSee RemarksFeb 08Buy91.903,260299,594178,904Feb 08 04:47 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62305,623Feb 05 04:39 PM
Smith Scott AndrewSee RemarksDec 19Option Exercise0.003,410046,233Dec 20 04:05 PM
KELLOGG PETER NSee RemarksDec 19Option Exercise0.003,410044,145Dec 20 04:04 PM
Curran TerrieSee remarksDec 19Option Exercise0.001,76505,690Dec 20 04:03 PM
Alles Mark JSee RemarksDec 19Option Exercise0.004,5500177,738Dec 20 04:02 PM
KAPLAN GILLADirectorDec 05Option Exercise24.979,250230,92685,551Dec 06 04:45 PM
MARIO ERNESTDirectorOct 30Option Exercise31.8013,600432,41271,024Nov 01 04:11 PM
KELLOGG PETER NSee RemarksOct 27Option Exercise0.002,100041,823Oct 31 04:10 PM
HUGIN ROBERT Jsee remarksOct 26Option Exercise31.8162,0201,972,5501,060,106Oct 26 04:44 PM
Curran TerrieSee remarksSep 25Sale143.891,727248,4983,925Sep 26 04:29 PM
KAPLAN GILLADirectorSep 12Option Exercise33.889,250313,39085,551Sep 14 04:35 PM
KAPLAN GILLADirectorSep 12Sale141.569,2501,309,43076,301Sep 14 04:35 PM
CASEY MICHAEL DDirectorSep 05Sale139.039,2501,286,0280Sep 06 06:53 PM
MARIO ERNESTDirectorAug 10Sale130.5218,5062,415,40369,424Aug 14 04:53 PM
KAPLAN GILLADirectorAug 02Sale134.527,5001,008,90076,301Aug 03 04:45 PM
Curran TerrieSee remarksAug 01Option Exercise0.001,50006,210Aug 02 04:38 PM
KELLOGG PETER NSee RemarksAug 01Option Exercise0.0060,000070,833Aug 02 04:37 PM
Smith Scott AndrewSee RemarksJul 28Option Exercise0.005,000045,415Aug 01 05:34 PM
PEHL MICHAEL F.See remarksJul 28Option Exercise0.002,50003,488Aug 01 04:56 PM
HUGIN ROBERT Jsee remarksJul 28Option Exercise0.0044,50001,021,159Aug 01 04:52 PM
Alles Mark JSee RemarksJul 28Option Exercise0.004,2000175,120Aug 01 04:48 PM
MARIO ERNESTDirectorJul 01Option Exercise0.00734087,930Jul 05 07:33 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00734024,361Jul 05 07:33 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073400Jul 05 07:31 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00734083,801Jul 05 07:32 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073400Jul 05 07:30 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00734023,880Jul 05 07:31 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00734012,066Jul 05 07:29 PM
LOUGHLIN JAMES JDirectorJun 26Option Exercise29.4318,500544,36332,877Jun 27 04:39 PM
LOUGHLIN JAMES JDirectorJun 26Sale133.5718,5002,471,04523,627Jun 27 04:39 PM
HUGIN ROBERT Jsee remarksJun 22Option Exercise29.49178,7205,271,0061,033,909Jun 23 04:02 PM
Friedman Michael ADirectorJun 22Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 22Sale135.005,000675,0000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Sale134.14175,97023,604,616973,909Jun 23 04:02 PM
CASEY MICHAEL DDirectorJun 21Option Exercise33.889,250313,3909,250Jun 23 04:05 PM
Friedman Michael ADirectorJun 21Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 21Sale130.005,000650,0000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Sale133.059,2501,230,7130Jun 23 04:05 PM
Friedman Michael ADirectorJun 19Option Exercise59.065,000295,3000Jun 20 04:07 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00333087,196Jun 20 04:09 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00333023,627Jun 20 04:08 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333083,067Jun 20 04:08 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
VESSEY RUPERTSee remarksJun 15Option Exercise104.164,007417,3584,785Jun 16 04:11 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375086,863Jun 16 04:11 PM
KAPLAN GILLADirectorJun 15Option Exercise0.00375082,734Jun 16 04:09 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.00375023,294Jun 16 04:10 PM
Haller Julia ADirectorJun 15Option Exercise0.003750575Jun 16 04:09 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 16 04:08 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.003750375Jun 16 04:06 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 16 04:06 PM
VESSEY RUPERTSee remarksJun 15Sale120.184,785575,0380Jun 16 04:11 PM
KAPLAN GILLADirectorJun 01Option Exercise28.979,250267,92682,359Jun 02 04:11 PM
CASEY MICHAEL DDirectorMay 30Option Exercise28.979,250267,926100,612May 31 04:10 PM